<DOC>
	<DOCNO>NCT00407966</DOCNO>
	<brief_summary>This phase II trial study side effect well give alvocidib together cytarabine mitoxantrone work treat patient newly diagnose acute myeloid leukemia . Drugs use chemotherapy , alvocidib , cytarabine , mitoxantrone , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell .</brief_summary>
	<brief_title>Alvocidib , Cytarabine , Mitoxantrone Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine efficacy toxicity flavopiridol ( alvocidib ) follow ara-C mitoxantrone adult newly diagnose acute myelogenous leukemia ( AML ) poor-risk feature . II . To determine disease free overall survival patient exhibit response treatment flavopiridol follow ara-C mitoxantrone . OUTLINE : Patients receive alvocidib IV 1 hour day 1-3 , cytarabine IV continuously 72 hour day 6-8 , mitoxantrone hydrochloride IV 1-2 hour day 9 . Beginning 35-63 day completion course 1 , patient achieve complete partial remission may receive second course treatment . Patients age 50 `` core binding factor '' acute myeloid leukemia ( AML ) ( e.g. , [ 8 ; 21 ] , inv [ 16 ] , [ 16 ; 16 ] ) achieve complete remission course 1 treatment may receive 3-4 course consolidation therapy comprise high-dose cytarabine discretion investigator . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Adults establish , pathologically confirm diagnose newly diagnose , poorrisk Acute Myeloid Leukemia ( AML ) include de novo secondary Acute Myeloid Leukemias exclude newly diagnose acute progranulocytic leukemia ( APL , M3 ) consider eligible study ECOG performance status 02 Patient must able give informed consent Serum creatinine = &lt; 2.0 ALT , AST = &lt; 5 x upper limit normal Bilirubin = &lt; 2.0 mg/dl Left ventricular ejection fraction &gt; = 45 % Newly diagnose AML , subtypes M0,1,2,47 exclude M3 ( APL ) poorrisk feature , include : Age &gt; 50 year , age &gt; 18 year one follow criterion : Antecedent hematologic disorder include myelodysplasia ( MDS ) relate AML ( MDS/AML ) prior myeloproliferative disorder ( MPD ) Treatmentrelated AML AML trilineage dysplasia ( AMLTLD ) Adverse cytogenetics ( defined 5/5q ; 7/7q ; abnormal 3q , 9q , 11q , 20q , 21q 17p ; ( 6 ; 9 ) ; ( 9 ; 22 ) ; trisomy 8 ; trisomy 13 , complex karyotype ( &gt; = 3 unrelated abnormality ) Patients receive hydroxyurea alone receive noncytotoxic therapy previously MDS MPD ( e.g. , thalidomide lenalidomide , interferon , cytokine , lowdose 5azacytidine , lowdose cytoxan ) eligible trial Any previous treatment flavopiridol Concomitant chemotherapy , radiation therapy , immunotherapy Hyperleukocytosis &gt; = 50,000 blasts/uL ; leukapheresis hydroxyurea may use immediately prior study drug administration cytoreduction ; must stop 24 hour first dose Flavopiridol Acute Progranulocytic Leukemia ( APL , M3 ) Active CNS leukemia Active , uncontrolled infection ; patient infection active treatment control antibiotic eligible Presence lifethreatening illness Patients mental deficit and/or psychiatric history preclude form give informed consent follow protocol Pregnant nursing patient exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>